Results 31 to 40 of about 14,860 (180)

Low Dopamine D2/D3 Receptor Availability is Associated with Steep Discounting of Delayed Rewards in Methamphetamine Dependence. [PDF]

, 2015
BackgroundIndividuals with substance use disorders typically exhibit a predilection toward instant gratification with apparent disregard for the future consequences of their actions.
Ballard, Michael E, Dean, Andy C, Hsu, Eustace, Ishibashi, Kenji, London, Edythe D, Mandelkern, Mark A, Monterosso, John R, Robertson, Chelsea L   +7 more
core   +3 more sources

Characteristics of first-time varenicline users – A cross-sectional study in Finnish quitters

BMC Public Health, 2017
Background Varenicline is an efficacious medicine for smoking cessation (SC) but little is known about the characteristics of varenicline users. This study examined the characteristics of first-time (naïve) varenicline users in Finland and compared those
Hanna E. Tervonen, Juha H. O. Turunen, Christine L. Baker, Juha Laine, Kari Linden   +4 more
doaj   +1 more source

Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trialResearch in context

The Lancet Regional Health. Europe
Summary: Background: Alcohol use disorder (AUD) is associated with an enormous burden of disease and cost to society. The dopamine deficiency hypothesis posits that negative reinforcement generated by a low brain dopamine state drives ethanol intake ...
Bo Söderpalm, Helga Lidö, Johan Franck, Anders Håkansson, Daniel Lindqvist, Markus Heilig, Joar Guterstam, Markus Samuelson, Barbro Askerup, Cecilia Wallmark-Nilsson, Andrea de Bejczy   +10 more
doaj   +1 more source

Evaluation of reproductive and renal toxicity of varenicline in male rats [PDF]

Iranian Journal of Basic Medical Sciences, 2019
Objective(s): Varenicline is a selective partial agonist for the nicotinic acetylcholine receptor a4b2 subtype, which is widely used to treat smoking addiction. However, there is still no data about its potential toxic effects on tissues.
Fatih OĞUZ, Ali Beytur, Elif Taşlıdere, Hakan Parlakpınar, Hilal Oğuz, Alaaddin Polat, İbrahim Topcu, Nigar Vardi, Engin Burak Selcuk   +8 more
doaj   +1 more source

Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats [PDF]

, 2015
Background: Alcohol and nicotine are largely co-abused. Here, we investigated whether concurrent exposure to both addictive drugs influences each other's consumption and whether varenicline attenuates alcohol consumption in the presence of nicotine ...
Ciccocioppo, Roberto, Cippitelli, Andrea, Scuppa, Giulia, Toll, Lawrence, Ubaldi, Massimo   +4 more
core   +1 more source

Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation

Preventive Medicine Reports, 2015
Objectives: A recent trial showed the clinical benefit of retreatment with varenicline in subjects failing on the initial treatment, or relapsing after initial success.
Lieven Annemans, Sophie Marbaix, Kristiaan Nackaerts, Pierre Bartsch   +3 more
doaj   +1 more source

Economic evaluation of smoking cessation in Ontario's regional cancer programs. [PDF]

, 2018
Quitting smoking after a diagnosis of cancer results in greater response to treatment and decreased risk of disease recurrence and second primary cancers.
Cameron, Erin, Chan, Kelvin, Djalalov, Sandjar, Evans, William, Hoch, Jeffrey S, Isaranuwatchai, Wanrudee, Masucci, Lisa, Mittmann, Nicole, Peter, Alice, Rabeneck, Linda, Truscott, Rebecca   +10 more
core   +1 more source

An update of a systematic review and meta‐analyses exploring flavours in intervention studies of e‐cigarettes for smoking cessation

Addiction, Volume 120, Issue 4, Page 770-778, April 2025.
Abstract Aims To determine patterns of e‐cigarette flavour use (sweet, tobacco, menthol/mint) in interventional studies of e‐cigarettes for stopping smoking, and to estimate associations between flavours and smoking/vaping outcomes. Methods Update of secondary data analyses, including meta‐analyses subgrouped by flavour provision and narrative ...
Nicola Lindson, Jonathan Livingstone‐Banks, Ailsa R. Butler, David T. Levy, Phoebe Barnett, Annika Theodoulou, Caitlin Notley, Nancy A. Rigotti, Yixian Chen, Jamie Hartmann‐Boyce   +9 more
wiley   +1 more source

Varenicline is More Effective than Nicotine Replacement Therapy During Pregnancy: Findings from the Smoking MUMS (Maternal Use of Medications and Safety) Study

International Journal of Population Data Science, 2018
Introduction Studies in the general population suggest that varenicline is more effective than nicotine replacement therapy (NRT) for smoking cessation.
Stephanie KY Choi, Duong T Tran, David B Preen, Deborah Randall, Anna Kemp-Casey, Kristjana Einarsdottir, Louisa R Jorm, Alys Havard   +7 more
doaj   +1 more source

Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): A randomized controlled clinical trial.

PLoS ONE, 2020
IntroductionVarenicline tartrate is superior for smoking cessation to other tobacco cessation therapies by 52 weeks, in the outpatient setting. We aimed to evaluate the long-term (104 week) efficacy following a standard course of inpatient-initiated ...
Kristin V Carson-Chahhoud, Brian J Smith, Matthew J Peters, Malcolm P Brinn, Faisal Ameer, Kuljit Singh, Robert Fitridge, Simon A Koblar, Jim Jannes, Antony J Veale, Sharon Goldsworthy, Khin Hnin, Adrian J Esterman   +12 more
doaj   +1 more source